echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Post-study exploration analysis of the ARIEL3 trial.

    J Clin Oncol: Post-study exploration analysis of the ARIEL3 trial.

    • Last Update: 2020-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The Phase 3 ARIEL3 study compared the clinical efficacy of rucaparib and placebo maintenance for the treatment of relapsed ovarian cancer, and showed that Rucapari had significant clinical benefits compared to placebo.
    Oza and others conducted an ex post-mortem analysis of the trial to assess quality-corrected progress-free lifetime (QA-PFS) and asymptomatic or toxic time (Q-TWiST).
    ARIEL3 were randomly assigned to the Rukapali group (600 mg 2/day) or placebo group in patients with platinum-sensitive, relapsed ovarian cancer.
    as of April 15, 2017, the average QA-PFS in the Rukapali group (375) was significantly longer than in the placebo group (189) (a difference of 6.28 months); In the (HRD) queue (236 vs 118) and the patients with low BRCA wild or miscellaneous absence (LOH) (107 vs 54), the average QA-PFS in the Rukapali group was also significantly longer than in the placebo group (differences of 9.37 months, 7.93 months and 2.71 months, respectively).
    the average Q-TWiST difference between the Rukapali group and the placebo group in the ITT population, BRCA mutation queue, HRD queue and BRCA wild type/LOH low patient group was 6.88 months, 9.73 months, 8.11 months and 3.35 months, respectively, using TOX defined by level 3 TEAE.
    summary: The significant difference between QA-PFS and Q-TWiST between Rukapali and placebo proves that Rukapali's benefits are significantly better than that of placebo in all predetermined queues.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.